Ardelyx (ARDX) vs Immix Biopharma (IMMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Immix Biopharma (IMMX) has outperformed Ardelyx (ARDX) over the past year, gaining 278.1% versus a loss of 36.9%. Ardelyx is the larger company by market cap ($841.7 million vs $786.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | IMMX |
|---|---|---|
| Share price | $3.26 | $9.49 |
| Market cap | $841.69M | $786.75M |
| 1-day change | -1.51% | -1.56% |
| YTD return | -44.08% | +81.45% |
| 1-year return | -36.94% | +278.09% |
| 5-year return | +201.85% | — |
| Forward P/E | 11.22 | — |
| EPS (TTM) | $-0.23 | $-0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $15.10 |
| 52-week low | $3.22 | $2.31 |
| Distance from 52-week high | -61.19% | -37.15% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +295.71% | +156.06% |
| Average volume | 4.08M | 1.66M |
| Shares outstanding | 258.19M | 82.90M |
| Employees | 489 | 21 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMMX has outperformed ARDX by 315.0 percentage points over the past year.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About Immix Biopharma
IMMX stock →Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos.
Healthcare · Biotechnology · 21 employees
ARDX vs IMMX FAQ
Which is bigger, Ardelyx or Immix Biopharma?
Ardelyx (ARDX) is larger, with a market capitalization of $841.69M compared with $786.75M for Immix Biopharma (IMMX).
Which stock has performed better over the past year, ARDX or IMMX?
IMMX returned +278.09% over the past 12 months, compared with -36.94% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and Immix Biopharma in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.